“Hopefully, before we believe that these biopharmaceutical giants — who have hundreds of their own broad genus claims — simply had their ‘I came to Jesus moment,’ the Supreme Court decided that sheepskins You might suspect a wolf in a hood.”
The U.S. Supreme Court is poised to soon decide the fate of the enablement requirement, and the patent community is uniformly gasping, wondering whether the court will deal a fatal blow to the biopharmaceutical industry. . At the same time, all patents become harder and even easier and more challenging. Judges and their supporters will likely disagree, but the Supreme Court does not have a strong track record of getting patent matters objectively right, at least from an innovation-promoting perspective. Since the court handed down its ruling, eBay vs MercExchange, Virtually every decision affecting the patent system has weakened patent rights and made it easier to challenge the patents themselves.
The Supreme Court refused to hear Juno V. Kite, It’s hard not to hear the echoes from the Windswept Federal Circuit Court of Appeals’ arcane, arcane specification law.On being difficult to say, hear, and write, the Federal Circuit actual It ruled that to satisfy the written description requirement, a patent applicant must disclose both what he knows and what he does not know. This requirement to disclose the known and the unknown is not only recklessly ignorant, it is simply illogical, it is the exact type of standard, and to the right thinking people, the federal Lets legitimately question whether the Circuit Court really understands and not just what is going on. There are stakes, but if they understand anything. Needless to say, requiring patent applicants to disclose what they do not know is an unreasonable standard. The Federal Circuit may also require patent applicants to levitate. That’s a standard as attainable as disclosing what you don’t know.
Favourites of the Federal Circuit — Deviations from Established Law
in the Amgen The same thought process that said the Federal Circuit needed to disclose both the known and the unknown flows into the issue of validation aptly before the Supreme Court. At its core is the position that if a person invents broadly and achieves an important fundamental advance, it is simply not appropriate to claim all that is invented. , supports only narrow claims and inevitably leads to only small and incremental innovations. As with any written description, if applicant must describe and validate all known and unknown, the disclosure of hundreds, thousands, or tens of thousands of examples, or all embodiments appropriately validated It is mandatory to certify that this is not the case. Regardless of what a person skilled in the art understands, Applicant:
Until the Federal Circuit deviated from the recently established law, Amgen, the law of activation was clear and rather uncontroversial. Patent applicants were required to provide sufficient information in their applications to enable relevant engineers in the technical field to make and use their inventions without undue experimentation.of Amgen, By conflating the basic question, “Can one skilled in the art make and use the invention?” , set a new course for enablement. In the past, excessive experimentation was done when, after a lot of effort and a lot of investment, those skilled in the art could not make and use the invention. But it’s not.
A description of an invention in a patent application does not have to be at the level of blueprint detail. If this requirement to specifically disclose all antibodies is upheld, the situation will change. Where all embodiments are specifically disclosed and must be specifically taught, the patent disclosure will teach those skilled in the art, regardless of what those skilled in the art may understand based on their reading of the disclosure. It should contain all the engineering-level details, not just enough information to in art. This is a major departure from existing law, with hundreds of thousands of patents immediately invalidated, and virtually all patents, if not yet valid, suddenly legal under this “super-enablement” standard. You will be able to file an objection.
dig deeper Amgen
Pages 11-15 of Amgen’s introductory overview provide a comprehensive description of the teachings of Amgen’s patents. The patent includes 26 antibody examples and detailed instructions for making additional antibodies within the genus, which Amgen calls a “roadmap.” Looking at the patent, it is nearly 400 pages long and comes with a CD Rom of X-ray crystal structure coordinates for Amgen’s “anchor” (or lead) antibodies 21B12 (Repatha) and 31H4. Amgen experts testified that the patent is a “rich handbook” and provides “a wealth of information” about the claimed antibodies. about. 3910 (763:1-12). He also testified that those skilled in the art following the patent’s roadmap “would certainly all make” the antibodies of the entire claim. 3909 (762:10-20), 3908 (757:12-14).
Sanofi Regeneron argues that its four antibodies, Praluent (alirocumab) and third-party PCSK9 antibodies from Merck (1D05) and Pfizer (J16), cannot be made using the patent disclosure. bottom. Resp. CABr. 11-15. Unfortunately for Sanofi-Regeneron, the jury dismissed that claim. And that claim was dismissed not only because it was unbelievable, but because it was directly refuted. I explained in detail what to generate. 3909 (760:2-21).
Neither the Federal Circuit nor Sanofi-Regeneron identified actual antibodies that would require undue experimentation to make using the patent’s teachings. At least, the term “excessive experimentation” has been used historically up to this point in patent history. and create a new caveat on the requirement that it can be used. That is, the entire invention can be made and used in a reasonable amount of time. This was not what the enablement requirements mandated. This is a warning bastard about over-experimentation. Simply put, there is no credible evidence or argument in court that the full and complete nature of the disclosed invention has not been fully realized. Just because there is does not mean that undue or any other level of experimentation is required.
The mere fact that it takes time and routine effort to create and use additional examples of the invention cannot be equated with excessive experimentation. The Federal Circuit Court of Appeals was erroneous and must reverse the decision. Failure to do so will result in the termination of patents for ground-breaking and pioneering innovations. It is important and tragic because it leads to a shift towards innovation.
unlikely Amici
| And this raises another important question: Why are so many pharmaceutical innovators arguing in court that broad genus claims are bad for innovation? , you should know that’s not true, but companies like Eli Lilly and Genentech (see US Patent 7,674,459); 7,935,791; and 8,563,695) and Johnson & Johnson (see U.S. Patents 7,491,391; 8,574,579; and 7,247,711) question the need for generic claims and broad patent protection. Is this because each of these companies has suffered heavy losses due to widespread genus claims?Ironically, Eli Lilly, a multi-year generic maker turned innovator at times, gave Teva a $100 million It caused $76.5 million in damage. See Teva vs Eli LillyNo. 1:18-cv-12029 (D.Mass).
So, hopefully, before we believe these biopharmaceutical giants (who have hundreds of broad genus claims of their own) simply “came to Jesus,” the Supreme Court will be a wolf in sheep’s clothing. Eli Lilly and others seem far more likely victims of very short-term thinking. So management has come to say that what they’ve been doing all along is an abomination to innovation. Or, for example, Eli Lilly may be acknowledging that it cannot compete with Teva in advancing innovation and that the patent system needs to change. To reward incremental, bite-sized innovation without putting up real roadblocks or giving a monopoly to creativity. . |
Image Source: Deposit Photo
Image ID: 63773275
Copyright: Evelyn
